Company / Shareholders' Equity
Allogene Therapeutics, Inc. Shareholders' Equity History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$292.5M
FY2025
5-year range
$292.5M / $666.9M
FY2021-FY2025
Trend
-42.9%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from $667M to $293M over the past 2 years.
Based on SEC 10-K filings.
$293M in FY2025 with a 3-year CAGR of -24.0%.
Declined from $667M to $293M over the past 2 years.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- -24.0%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of -24.0%, indicating a declining trend.
- In FY2025, shareholders' equity decreased 42.9% year-over-year.
- Peak shareholders' equity was recorded in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -4.27 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $292.5M | -42.9% |
| FY2024 | $512.2M | -23.2% |
| FY2023 | $666.9M | +0.0% |
| FY2022 | $666.9M | +6.0% |
| FY2021 | $629.0M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026